Biobanking Co-op

Moderna adds Chief Operating Officer role as company expands into oncology. Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, Mass., September 30, 2026 (Newswire.com) - Moderna, Inc. (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company. The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio. The Company has also expanded the infectious disease franchise, which now includes five approved vaccines following the recent U.S. FDA approval of Moderna's seasonal flu vaccine and the European Commission marketing authorization of the Company's seasonal flu plus COVID combination vaccine. Juan Andres will return to Moderna as Chief Operating Officer, effective October 5, 2026. Mr. Andres will report to Chief Executive Officer Stéphane Bancel and serve on the Company's Executive Committee. As Chief Operating Officer, Mr. Andres will work across the Company to help drive focus, prioritization and execution while leading the manufacturing organization. Moderna also announced that Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, has decided to retire from the Company. "I am very pleased to welcome Juan back to Moderna as our Chief Operating Officer," said Stéphane Bancel, Chief Executive Officer of Moderna. "As we enter the next chapter of Moderna, Juan's experience leading complex global operations will be invaluable. He knows Moderna deeply and was an extraordinary partner to me as we built and scaled the Company. I look forward to working with him again as we execute on our strategy." Mr. Andres previously spent nearly six years at Moderna, joining the Company in 2017 and serving as Chief Technical Operations and Quality Officer from 2018 through 2022. He later served as President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023. During his tenure, he led the build-out and unprecedented scale-up of Moderna's manufacturing capabilities, including the rapid expansion of the Company's global manufacturing network to support the production and supply of Moderna's COVID-19 vaccine. "I am excited to return to Moderna at such an important moment for the Company," said Mr. Andres. "Moderna has always been a special place to me, and the opportunity ahead is tremendous. I look forward to working with Stéphane and colleagues across the Company to execute on our priorities and deliver more mRNA medicines to patients around the world." "I am also deeply grateful to Jerh for his leadership, partnership and commitment to Moderna over the past four years," said Mr. Bancel. "He has made significant contributions to our Company and built a very strong team that will carry forward the important work of manufacturing and technical operations. I wish Jerh and his family all the best in his retirement." "It has been a privilege to be part of Moderna and to lead our Technical Operations and Quality organization," said Dr. Collins. "I am incredibly proud of what our teams have accomplished together for patients, and grateful to the many colleagues I have had the opportunity to work alongside. As I look ahead to retirement, I have great confidence in the team and in Moderna's future." Dr. Collins joined Moderna in October 2022 and became Chief Technical Operations and Quality Officer in January 2023. During his tenure, he helped transition Moderna's manufacturing footprint for an endemic vaccine market, advanced the Company's manufacturing capabilities in the UK, Canada and Australia, and established the manufacturing model to support intismeran autogene. Prior to Moderna, he spent nearly 30 years at Novartis in roles of increasing responsibility across pharmaceutical production and manufacturing. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company's appointment of Mr. Andres as Chief Operating Officer, the potential launch and scale-up of intismeran autogene, the advancement of Moderna's business and oncology portfolio, and the Company's strategy, priorities and plans to deliver mRNA medicines. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof. Moderna Contacts Media: Chris Ridley Vice President, Global Head of Communications +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected]

After Moderna's dizzying rally, it's time to sell, says analyst. * ALLISON GATLIN * Updated 04:11 PM ET 09/30/2026 After nearly quadrupling over the past month, it's time to get out of Moderna (MRNA) stock, a Citi analyst said Wednesday as he downgraded shares to a sell rating. Citi's Geoff Meacham's downgrade comes alongside a price target hike to 80 from 60, according to reports from MarketWatch and Barron's. Meacham arrived at the new price target by refining his sales and operating expense assumptions. Biotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market On this episode of Growth Stories, Investor’s Business Daily, LLC take a look at the groundbreaking tests that could revolutionize cancer detection and what investors need to know about this evolving market. Biotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market See All Videos Still, it's not enough to justify Moderna's valuation following an "outsized run" that began on Aug. 19 following upbeat news for the Merck (MRK)-partnered cancer vaccine, intismeran autogene, or INT. Citi declined to share the analyst's note with Investor's Business Daily. "While intismeran could become a market leading therapy in melanoma, we believe the re-rating now reflects successful expansion in many tumor types and unrealistic implied sales," Meacham said. In response to the downgrade, Moderna stock tumbled 5.4% to 192.57. Moderna's towering market cap. The massive run sent Moderna's market cap north of $81 billion, according to MarketSurge. That closely mirrors Regeneron Pharmaceuticals' (REGN) $77 billion cap. But, while Regeneron is massively profitable with growing sales, the same can't be said for Moderna. A lot hinges on the cancer vaccine, which has only shown promise in melanoma. The companies said in August that patients given intismeran autogene in combination with Keytruda, Merck's blockbuster cancer drug, were less likely to relapse than those who received Keytruda alone. Meacham says Moderna and Merck will score a "clear win" if the combination lowers the risk of recurrence by 35%. Cutting the odds of relapse by 28% would be a "clinical credible," he said. But the biggest driver behind Moderna stock are what Meacham says are outsized expectations for the therapeutic vaccine to work in other cancers. The companies are running nine other studies of intismeran autogene, including in kidney, lung and bladder cancers. But those cancers are vastly different from melanoma, which is considered an easy cancer to treat. Moderna stock's high rating. The downgrade puts Meacham in a small group of bearish voices. Of the 27 analysts who cover Moderna stock on FactSet, just two - not including Meacham - rate it a sell or equivalent. Six have buy ratings and 10 are hold-rated on the stock. Still, Moderna stock retains a strong IBD Relative Strength Rating of 99. This means shares are in the top 1% of all stocks when it comes to 12-month performance. IBD newsletters. Get exclusive IBD analysis and actionable news daily. Follow Allison Gatlin on X/Twitter at @AGatlin_IBD. YOU MAY ALSO LIKE:

Moderna has appointed Juan Andres as Chief Operating Officer, effective 5 October 2026, as the company expands its operations into oncology. Andres previously worked at Moderna from 2017 to 2023, leading the build-out of its manufacturing capabilities during the COVID-19 vaccine scale-up. The new role supports Moderna's preparation for the potential launch of intismeran autogene following positive Phase 3 results and the advancement of its broader oncology portfolio. The company's infectious disease franchise now includes five approved vaccines, following recent US FDA approval of its seasonal flu vaccine and European Commission authorisation of its flu-COVID combination vaccine. Jerh Collins, Chief Technical Operations and Quality Officer, will retire after four years with the company. Andres will oversee manufacturing operations and work across the organisation to drive execution of Moderna's strategy.